|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRPR |
Gene summary for SRPR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRPR | Gene ID | 6734 |
| Gene name | SRP receptor subunit alpha | |
| Gene Alias | DP | |
| Cytomap | 11q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | P08240 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6734 | SRPR | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 6.49e-08 | 7.47e-01 | 0.1479 |
| 6734 | SRPR | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 7.14e-06 | 6.25e-01 | 0.1531 |
| 6734 | SRPR | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.56e-13 | 4.61e-01 | 0.1633 |
| 6734 | SRPR | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 6.05e-06 | 2.72e-01 | 0.1608 |
| 6734 | SRPR | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 1.98e-07 | 3.69e-01 | 0.1604 |
| 6734 | SRPR | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.75e-15 | 5.49e-01 | 0.1621 |
| 6734 | SRPR | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 2.17e-08 | 5.79e-01 | 0.1619 |
| 6734 | SRPR | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 2.91e-04 | 4.58e-01 | 0.159 |
| 6734 | SRPR | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.73e-08 | 4.58e-01 | 0.1602 |
| 6734 | SRPR | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.70e-04 | 3.60e-01 | 0.1608 |
| 6734 | SRPR | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.14e-06 | 5.30e-01 | 0.1622 |
| 6734 | SRPR | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 6.06e-08 | 3.23e-01 | 0.1575 |
| 6734 | SRPR | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 5.51e-03 | 2.58e-01 | 0.1545 |
| 6734 | SRPR | P1_cSCC | Human | Skin | cSCC | 4.91e-18 | 5.91e-01 | 0.0292 |
| 6734 | SRPR | P2_cSCC | Human | Skin | cSCC | 9.81e-21 | 4.56e-01 | -0.024 |
| 6734 | SRPR | P4_cSCC | Human | Skin | cSCC | 3.35e-32 | 7.25e-01 | -0.00290000000000005 |
| 6734 | SRPR | P10_cSCC | Human | Skin | cSCC | 2.47e-24 | 5.91e-01 | 0.1017 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000660524 | Oral cavity | EOLP | protein targeting | 68/2218 | 314/18723 | 4.95e-07 | 1.34e-05 | 68 |
| GO:007097223 | Oral cavity | EOLP | protein localization to endoplasmic reticulum | 22/2218 | 74/18723 | 2.93e-05 | 4.23e-04 | 22 |
| GO:007259921 | Oral cavity | EOLP | establishment of protein localization to endoplasmic reticulum | 15/2218 | 46/18723 | 1.71e-04 | 1.78e-03 | 15 |
| GO:004504721 | Oral cavity | EOLP | protein targeting to ER | 12/2218 | 42/18723 | 2.71e-03 | 1.62e-02 | 12 |
| GO:009015022 | Oral cavity | EOLP | establishment of protein localization to membrane | 45/2218 | 260/18723 | 5.73e-03 | 2.94e-02 | 45 |
| GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
| GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
| GO:00709728 | Prostate | BPH | protein localization to endoplasmic reticulum | 36/3107 | 74/18723 | 1.61e-10 | 9.22e-09 | 36 |
| GO:009015016 | Prostate | BPH | establishment of protein localization to membrane | 77/3107 | 260/18723 | 1.06e-07 | 2.56e-06 | 77 |
| GO:00725997 | Prostate | BPH | establishment of protein localization to endoplasmic reticulum | 23/3107 | 46/18723 | 1.71e-07 | 3.85e-06 | 23 |
| GO:00450476 | Prostate | BPH | protein targeting to ER | 21/3107 | 42/18723 | 5.88e-07 | 1.15e-05 | 21 |
| GO:00066134 | Prostate | BPH | cotranslational protein targeting to membrane | 15/3107 | 31/18723 | 4.00e-05 | 4.30e-04 | 15 |
| GO:0006614 | Prostate | BPH | SRP-dependent cotranslational protein targeting to membrane | 10/3107 | 26/18723 | 6.33e-03 | 2.89e-02 | 10 |
| GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
| GO:000660519 | Prostate | Tumor | protein targeting | 109/3246 | 314/18723 | 6.11e-14 | 7.30e-12 | 109 |
| GO:007097216 | Prostate | Tumor | protein localization to endoplasmic reticulum | 36/3246 | 74/18723 | 5.66e-10 | 2.95e-08 | 36 |
| GO:007259913 | Prostate | Tumor | establishment of protein localization to endoplasmic reticulum | 23/3246 | 46/18723 | 3.87e-07 | 8.56e-06 | 23 |
| GO:009015017 | Prostate | Tumor | establishment of protein localization to membrane | 77/3246 | 260/18723 | 6.46e-07 | 1.33e-05 | 77 |
| GO:004504713 | Prostate | Tumor | protein targeting to ER | 21/3246 | 42/18723 | 1.24e-06 | 2.31e-05 | 21 |
| GO:000661312 | Prostate | Tumor | cotranslational protein targeting to membrane | 15/3246 | 31/18723 | 6.78e-05 | 7.21e-04 | 15 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0306026 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa0306036 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa030608 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306011 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306021 | Liver | HCC | Protein export | 21/4020 | 23/8465 | 1.20e-05 | 8.53e-05 | 4.74e-05 | 21 |
| hsa0306031 | Liver | HCC | Protein export | 21/4020 | 23/8465 | 1.20e-05 | 8.53e-05 | 4.74e-05 | 21 |
| hsa0306018 | Oral cavity | OSCC | Protein export | 21/3704 | 23/8465 | 2.42e-06 | 1.27e-05 | 6.45e-06 | 21 |
| hsa0306019 | Oral cavity | OSCC | Protein export | 21/3704 | 23/8465 | 2.42e-06 | 1.27e-05 | 6.45e-06 | 21 |
| hsa0306025 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306035 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306016 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306017 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306024 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| hsa0306034 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |